Global Amyotrophic lateral sclerosis (ALS) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431907
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • AB Science
  • Avicena Group
  • Biogen
  • BrainStorm Therapeutics
  • Covis Pharmaceutical Inc.
  • Cytokinetics Inc.
  • MORE
Amyotrophic lateral sclerosis (ALS) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global amyotrophic lateral sclerosis treatment market was valued at US$ 51.04 Mn in 2016, and is expected to reach US$ 306.6 Mn by 2025, expanding at a CAGR of 21.1% from 2017 to 2025.

Market Insights

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes death of nerve cells that control voluntary muscles. According to National Organization for Rare Disorders (NORD), ALS is a is a rare disorder that affects approximately 30,000 people in the United States, approximately 5,000 new cases are diagnosed each year in the United States. Currently, there is no cure for ALS however, treatments are available to control symptoms and to prevent complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS it includes Riluzole and Edaravone, other medications are prescribe to control ALS symptoms. It is studied that in the base year 2016, Riluzole (Rilutek) was major revenue generating segment because riluzole was the only approved drug for a treatment of ALS, however patent expiry of Rilutek in 2013 has been negatively impacting the ALS treatment market growth. On the other hand, recently approved medication Edaravone (Radicava) expected to show highest growth rate during forecast period due to its applicability and higher cost would drive market growth. Moreover strong pipeline molecule such as AB-1010 (masitinib), Methycobal (mecobalamin), Arimoclomol, CK-2017357 (CK-357, tirasemtiv) would assist ALS treatment market growth during forecast period. It is observed that, in the base year 2016, North America was dominating ALS treatment market in terms of revenue due to the factors such as upsurge in funding by government agencies and private organizations in healthcare system, increase in prevalence of the neurological diseases and higher treatment awareness are fueling market growth in North America. It is anticipated that, Asia Pacific will grow significantly during forecast period due to increasing healthcare awareness, increasing partnership of key players such as Biogen, Avicena, Mitsubishi Tanabe, and Sanofi with local manufacturer, populous countries and developing economic condition would fuel ALS treatment market growth.

Market Competition Assessment

The Amyotrophic lateral sclerosis (ALS) market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as AB Science, Avicena Group, Biogen, BrainStorm Therapeutics, Covis Pharmaceutical Inc., Cytokinetics Inc., Eisai Co. Ltd., GlaxoSmithKline plc., Ionis Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corp., Neuralstem Inc., Neuraltus Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Nutra Pharma Corp., Pharnext SAS, Q-Therapeutics Inc. and other.

Key Market Movements:
  • Factors such as increasing treatment awareness, increase in incidence of ALS, strong pipeline molecules, rising geriatric population, favorable reimbursement policies in some countries and expected launch of newer medication would drive the growth of ALS treatment market globally.
  • Due to the higher number of unmet needs, manufacturers in the market are focusing on innovation and technological advances in treatment options would further influence the growth of ALS treatment market globally.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Science
  • Avicena Group
  • Biogen
  • BrainStorm Therapeutics
  • Covis Pharmaceutical Inc.
  • Cytokinetics Inc.
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Snapshot
2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, Drug Type
2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share, by Geography, 2016 (Value %)

Chapter 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment Market
3.4 Epidemiology of Amyotrophic lateral sclerosis (ALS)
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Amyotrophic Lateral Sclerosis (ALS) Treatment Market

Chapter 4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type
4.1 Overview
4.2 Top 3 Countries
4.3 Riluzole
4.4 Edaravone
4.5 Other

Chapter 5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.5.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 AB Science
6.2 Avicena Group
6.3 Biogen
6.4 BrainStorm Therapeutics
6.5 Covis Pharmaceutical Inc.
6.6 Cytokinetics Inc.
6.7 Eisai Co. Ltd.
6.8 GlaxoSmithKline plc.
6.9 Ionis Pharmaceuticals, Inc.
6.10 Mitsubishi Tanabe Pharma Corp.
6.11 Neuralstem Inc.
6.12 Neuraltus Pharmaceuticals Inc.
6.13 Newron Pharmaceuticals S.p.A.
6.14 Nutra Pharma Corp.
6.15 Pharnext SAS
6.16 Q-Therapeutics Inc.

List of Figures
Fig. 1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Research Methodology
Fig. 2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2016 (US$ Mn)
Fig. 3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share, by Geography, 2016 (Value %)
Fig. 4 Attractive Investment Proposition: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Geography, 2016
Fig. 5 Global Riluzole Market, 2015 - 2025 (US$ Mn)
Fig. 6 Global Edaravone Market, 2015 - 2025 (US$ Mn)
Fig. 7 Global Other ALS Treatment Drugs Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Market Positioning of Key Players in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Table 2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015 - 2025 (US$ Mn)
Table 3 Top 3 Countries in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2015 - 2025 (US$ Mn)
Table 4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Geography, 2015 - 2025 (US$ Mn)
Table 5 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
Table 6 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 7 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
Table 8 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 9 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
Table 10 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 11 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
Table 12 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 13 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
Table 14 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 - 2025 (US$ Mn)
Table 15 AB Science: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 16 Avicena Group: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 17 Biogen: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 18 BrainStorm Therapeutics: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 19 Covis Pharmaceutical Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 20 Cytokinetics Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 21 Eisai Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 22 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 23 Ionis Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 24 Mitsubishi Tanabe Pharma Corp.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 25 Neuralstem Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 26 Neuraltus Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 27 Newron Pharmaceuticals S.p.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 28 Nutra Pharma Corp.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 29 Pharnext SAS: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 30 Q-Therapeutics Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AB Science
  • Avicena Group
  • Biogen
  • BrainStorm Therapeutics
  • Covis Pharmaceutical Inc.
  • Cytokinetics Inc.
  • Eisai Co. Ltd.
  • GlaxoSmithKline plc.
  • Ionis Pharmaceuticals, Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Neuralstem Inc.
  • Neuraltus
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll